Guy Strauss, DO
Internal Medicine · Lake City, FLNPI 1578570727
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,918 of the $9,672 with a category attached, or 71.5%. 44 manufacturers reported payments, led by Amarin Pharma, Inc. at 26.0% of the total. Reporting peaked in 2019 at $4,060 and has fallen 80.9% since, to $775 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 512 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$3K
- Novo Nordisk$1K
- Novartis$535
- Johnson & Johnson$530
- Amgen$488
- AstraZeneca$483
- plus $4K from 38 others
Across 928 payments — averaging $15,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$7.9M
- Pfizer$2.9M
- Abbott$1.7M
- Biohaven Pharmaceuticals, Inc.$650K
- AstraZeneca$367K
- Biohaven Pharmaceutical Holding Company Ltd.$205K
- plus $215K from 6 others
What the payments were for
- Consulting fees$3003%
- Speaking & faculty fees$2,25023%
- Travel & lodging$1902%
- Food & beverage$6,91872%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,673 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 169 | $178,688 |
| OzempicSemaglutide | 96 | $143,312 |
| FarxigaDapagliflozin Propanediol | 82 | $100,312 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $87,261 |
| JardianceEmpagliflozin | 64 | $70,950 |
| EntrestoSacubitril/Valsartan | 41 | $54,815 |
| Repatha SureclickEvolocumab | 45 | $43,687 |
| JanuviaSitagliptin Phosphate | 32 | $37,664 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $33,568 |
| XareltoRivaroxaban | 21 | $28,271 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 82 | $26,076 |
| TrulicityDulaglutide | 19 | $21,440 |
| MyrbetriqMirabegron | 17 | $20,214 |
| RybelsusSemaglutide | 13 | $15,748 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 52 | $11,494 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $403 | $204,763251 claims |
| Novo NordiskOzempic, Rybelsus | $1,187 | $159,060109 claims |
| AstraZenecaFarxiga | $483 | $100,31282 claims |
| GSKTrelegy Ellipta, Shingrix | $183 | $98,755130 claims |
| Boehringer IngelheimJardiance | $262 | $70,95064 claims |
| NovartisEntresto | $535 | $54,81541 claims |
| MerckJanuvia | $337 | $37,66432 claims |
| Johnson & JohnsonXarelto | $530 | $28,27121 claims |
| Lilly USA, LLCTrulicity | $287 | $21,44019 claims |
| Astellas Pharma US IncMyrbetriq | $134 | $20,21417 claims |
| AbbVieSynthroid | $261 | $1,35815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Lake City
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.